By Barbara Obstoj-Cardwell. Editor
Last week saw the announcements of the biggest pharmaceutical M&A and licensing deals of the year. US biotech giant Amgen, which will soon be facing competition from biosimilars, agreed to fork out around $28 billion to acquire Horizon Therapeutics. Another US biotech, Clovis Oncology, has finally thrown in the towel, filing for Chapter 11 bankruptcy, and a “stalking-horse” deal with Novartis. Japan’s largest drugmaker Takeda announced a licensing deal with Nimbus Therapeutics for the latter’s autoimmune candidate NDI-034858, re-coded TAK-279, paying a massive $4 billion upfront.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze